MBII · Marrone Bio Innovations Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $44.31M | $38.37M | $29.37M | $21.22M | $18.17M | $14.04M |
| Cost of Revenue | $17.06M | $15.51M | $13.26M | $10.91M | $10.53M | $9.52M |
| Gross Profit | $27.25M | $22.87M | $16.11M | $10.31M | $7.64M | $4.52M |
| R&D | $11.11M | $10.32M | $12.92M | $9.68M | $9.71M | $8.65M |
| SG&A | $30.57M | $28.73M | $30.07M | $19.16M | $19.81M | $18.51M |
| Total Operating Expenses | $42.65M | $40.06M | $44.10M | $29.82M | $30.63M | $28.18M |
| D&A | $3.53M | $3.56M | $2.35M | $1.89M | $2.04M | $2.23M |
| Operating Income | ($15.40M) | ($17.20M) | ($27.98M) | ($19.50M) | ($23.00M) | ($23.66M) |
| Interest Expense | $1.57M | $1.44M | $1.47M | $2.06M | $3.37M | $2.94M |
| Income Tax | $45.0K | $29.0K | $28.0K | - | - | $0 |
| Net Income | ($16.55M) | ($20.17M) | ($37.17M) | ($20.21M) | ($30.93M) | ($31.07M) |
| EPS - Basic | ($0.14) | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.62M | $15.84M | $6.25M | $18.22M | $786.0K | $9.61M |
| Accounts Receivable | $13.21M | - | $5.92M | $2.72M | $3.79M | $3.59M |
| Inventory | $8.63M | $6.62M | $8.15M | $8.22M | $9.83M | $8.48M |
| Accounts Payable | $2.69M | $1.90M | $3.38M | $1.69M | $3.80M | $1.39M |
| Current Assets | $42.68M | $34.26M | $21.72M | $30.14M | $19.12M | $26.88M |
| Total Assets | $87.06M | $81.20M | $72.72M | $46.57M | $36.91M | $45.98M |
| Current Liabilities | $45.19M | $24.23M | $21.09M | $11.32M | $22.00M | $15.25M |
| Long-term Debt | $7.69M | $11.48M | $11.85M | $11.82M | $24.41M | $21.08M |
| Total Liabilities | $57.40M | $49.79M | $49.16M | $33.63M | $87.56M | $76.17M |
| Stockholders' Equity | $29.65M | $31.41M | $23.56M | $12.94M | ($50.65M) | ($30.18M) |
| Retained Earnings | ($357.37M) | ($340.82M) | ($320.65M) | ($283.47M) | ($265.57M) | ($234.65M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.96M) | ($15.96M) | ($21.34M) | ($21.06M) | ($21.06M) | ($24.31M) |
| Investing Cash Flow | ($1.84M) | ($1.80M) | ($6.79M) | ($580.0K) | ($814.0K) | ($209.0K) |
| Financing Cash Flow | $15.59M | $27.34M | $16.16M | $12.09M | $13.05M | $14.29M |
| CapEx | $1.09M | $559.0K | $296.0K | $580.0K | $849.0K | $209.0K |
| Free Cash Flow | ($11.05M) | ($16.52M) | ($21.64M) | ($21.64M) | ($21.91M) | ($24.52M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 61.5% | 59.6% | 54.9% | 48.6% | 42.0% | 32.2% |
| Operating margin | -34.8% | -44.8% | -95.3% | -91.9% | -126.6% | -168.5% |
| EBITDA margin | -26.8% | -35.5% | -87.3% | -83.0% | -115.3% | -152.6% |
| Net margin | -37.4% | -52.6% | -126.6% | -95.3% | -170.2% | -221.3% |
| Free cash flow margin | -24.9% | -43.0% | -73.7% | -102.0% | -120.6% | -174.6% |
| FCF / Net income | 0.67 | 0.82 | 0.58 | 1.07 | 0.71 | 0.79 |
| R&D / Revenue | 25.1% | 26.9% | 44.0% | 45.6% | 53.5% | 61.6% |
| SG&A / Revenue | 69.0% | 74.9% | 102.4% | 90.3% | 109.1% | 131.8% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -19.0% | -24.8% | -51.1% | -43.4% | -83.8% | -67.6% |
| Return on equity | -55.8% | -64.2% | -157.8% | -156.3% | 61.1% | 102.9% |
| Return on invested capital | -32.6% | -31.7% | -62.4% | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.94 | 1.41 | 1.03 | 2.66 | 0.87 | 1.76 |
| Quick ratio | 0.75 | 1.14 | 0.64 | 1.94 | 0.42 | 1.21 |
| Cash ratio | 0.43 | 0.65 | 0.30 | 1.61 | 0.04 | 0.63 |
| Leverage | ||||||
| Debt / Equity | 0.26 | 0.37 | 0.50 | 0.91 | -0.48 | -0.70 |
| Debt / Assets | 0.09 | 0.14 | 0.16 | 0.25 | 0.66 | 0.46 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -9.8x | -11.9x | -19.0x | -9.5x | -6.8x | -8.0x |
| Equity multiplier | 2.94 | 2.59 | 3.09 | 3.60 | -0.73 | -1.52 |
| Liabilities / Assets | 0.66 | 0.61 | 0.68 | 0.72 | 2.37 | 1.66 |
| Efficiency | ||||||
| Asset turnover | 0.51 | 0.47 | 0.40 | 0.46 | 0.49 | 0.31 |
| Inventory turnover | 1.98 | 2.34 | 1.63 | 1.33 | 1.07 | 1.12 |
| Days sales outstanding | 109d | - | 74d | 47d | 76d | 93d |
| Days inventory outstanding | 185d | 156d | 224d | 275d | 341d | 325d |
| Days payable outstanding | 57d | 45d | 93d | 57d | 132d | 53d |
| Cash conversion cycle | 236d | - | 205d | 265d | 285d | 365d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 15.5% | 30.6% | 38.4% | 16.8% | 29.4% | 43.3% |
| Revenue CAGR (3y) | 27.8% | 28.3% | 27.9% | 29.4% | 25.8% | 25.3% |
| Revenue CAGR (5y) | 25.8% | 31.4% | 26.3% | 24.3% | - | - |
| Gross profit growth (YoY) | 19.1% | 41.9% | 56.2% | 35.0% | 69.0% | 729.4% |
| Operating income growth (YoY) | 10.4% | 38.6% | -43.5% | 15.2% | 2.8% | 40.0% |
| Net income growth (YoY) | 17.9% | 45.7% | -83.9% | 34.6% | 0.5% | 28.9% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 33.1% | 23.7% | 0.0% | 1.2% | 10.7% | 35.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -5.6% | 33.3% | 82.1% | - | -67.8% | -1392.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$44.31M totalProduct$43.81M · 98.9%
License$498.0K · 1.1%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-3.32
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Agricultural Chemicals
Comparing MARRONE BIO INNOVATIONS INC against the 5 most active filers in the same SIC group.